Cannabis Science, Inc. (OTCBB:CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce the preparation to release of the second Cannabis Science brand formulation. The Company has been receiving a constant flow of inquires via its website, emails, and telephone calls for cannabis-extract based medicines. For example, cancer patients seeking extract-based formulations for topical or internal use have frequently contacted Cannabis Science. Manufacturing and packaging is being completed for release through Colorado state licensed dispensaries.

In light of the accumulating anecdotal reports of the successful cancer treatments with cannabis extracts, the Company will continue to keep patients updated on current peer-reviewed scientific literature supporting the historical and modern use of cannabis to treat "tumors”. Unlike conventional treatment, cannabis medicines have an outstanding safety profile allowing patients in states with medical marijuana laws to safely make informed decisions to legally self-administration of various cannabis-based preparations.

The second Cannabis Science Brand extract-based formulation is comprised of high quality extracts packaged in oral dispensing syringes for patient self-administration for treatment. This is a critical milestone for the Company in bringing its second formulation to market. Other formulations will be made available soon to medical marijuana patients in Colorado and other legal medical marijuana states, such as California through select California State licensed dispensaries. The Company’s intent is to work with specially appointed legal providers and laboratories to expand the availability of its formulations across the United States where legally available.

Dr. Robert Melamede, Ph.D., the Company’s CEO, said, “We hear from so many people wanting a reliable, high-quality formulation that they can self-administer to treat a wide variety ailments. A quality, standardized formulation is essential for long term care. Initially, we have chosen two State licensed facilities in Colorado to work with, both of the facilities were chosen for the quality of their botanicals and patient care. We are looking forward to expanding availability to other facilities in legal medical marijuana States, specifically California, along with an increased multiple formulation offerings.”

Social Network

Please visit http://www.facebook.com/pages/Cannabis-Science/216643278395932

Please visit http://twitter.com/#!/CannabisScienc1

At the same time Cannabis Science is proud to announce the release of their social network pages on Facebook and Twitter.

Facebook has over 250 million global users and over 600 million visitors half of which visit more than once a day.* Twitter has over 175 million* and has become a powerful media and marketing resource especially for a global company like Cannabis Science.

In reference to the social networks Dr. Robert Melamede said “One of our current goals at Cannabis Science is to increase communication and exposure on a global scale of the Cannabis Science mission to alleviate suffering and promote health through cannabinoid science. Facebook and Twitter are not only the resource but the catalyst.”

Dr. Melamede continued, “Cannabis Science Facebook and Twitter pages are an information resource in regards to the company and their operations. There will be updates on our first and second cannabis-extract-based formulations. More importantly, these pages will document how Cannabis Science is moving forward. Patients, medical professionals and all those interested in the scientific side of the medical cannabis industry can follow us and be included in the global conversation. We hope this conversation includes testimonials of people successes, tracks different patients ideas and possible product releases for different ailments. The ultimate goal of these Facebook and Twitter sites is to be a call to the world that includes discussion from patients and to have this conversation mature into a support campaign for the FDA.”

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

*Source Twitter API page, Business Insider, March 31, 2011 Nicholas Carlson